{"address1": "No. 1, Nan-Ke 8th Road", "address2": "Southern Taiwan Science Park Shan-Hua", "city": "Tainan City", "zip": "74144", "country": "Taiwan", "phone": "886 6 505 2888", "fax": "886 6 505 2898", "website": "https://www.scinopharm.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Chih-Hsien  Lo", "age": 65, "title": "Chairman & Gen. Chief Strategy Officer", "yearBorn": 1957, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Li-An  Lu", "title": "Pres & CEO", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Chih-Hui  Lin", "title": "Acting Financial Off., Sr. Director of Acct., Acct. Off., Acting Spokesperson & Corp. Gov. Off.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ling-Hsiao  Lien", "title": "Vice-Pres of Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Li-Chiao  Chang Chemistry, Ph.D.", "title": "VP of R&D Division and Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason  Chen", "title": "Director of HR & Admin", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ching-Wen  Lin B.S, M.S, Ph.D.", "title": "VP of Marketing & Sales and Chief Strategy Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shun Yang  Lin", "title": "Director of Corp. Devel.", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 2, "previousClose": 26.4, "open": 26.45, "dayLow": 26.15, "dayHigh": 26.45, "regularMarketPreviousClose": 26.4, "regularMarketOpen": 26.45, "regularMarketDayLow": 26.15, "regularMarketDayHigh": 26.45, "dividendRate": 0.48, "dividendYield": 0.0174, "exDividendDate": 1657152000, "payoutRatio": 1.0667, "fiveYearAvgDividendYield": 1.65, "beta": 0.396798, "trailingPE": 58.222225, "forwardPE": 36.38889, "volume": 1150369, "regularMarketVolume": 1150369, "averageVolume": 1157773, "averageVolume10days": 2195409, "averageDailyVolume10Day": 2195409, "bid": 26.2, "ask": 26.3, "bidSize": 0, "askSize": 0, "marketCap": 20717363200, "fiftyTwoWeekLow": 22.35, "fiftyTwoWeekHigh": 29.65, "priceToSalesTrailing12Months": 6.3471437, "fiftyDayAverage": 26.684, "twoHundredDayAverage": 25.762, "trailingAnnualDividendRate": 0.36, "trailingAnnualDividendYield": 0.013636365, "currency": "TWD", "enterpriseValue": 18245904384, "profitMargins": 0.10821, "floatShares": 243523958, "sharesOutstanding": 790739008, "heldPercentInsiders": 0.58967996, "heldPercentInstitutions": 0.1684, "impliedSharesOutstanding": 0, "bookValue": 13.216, "priceToBook": 1.9824456, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": 0.891, "netIncomeToCommon": 353216000, "trailingEps": 0.45, "forwardEps": 0.72, "lastSplitFactor": "1040:1000", "lastSplitDate": 1502323200, "enterpriseToRevenue": 5.59, "enterpriseToEbitda": 22.007, "52WeekChange": 0.17333329, "SandP52WeekChange": 0.026524067, "lastDividendValue": 0.48, "lastDividendDate": 1657152000, "exchange": "TAI", "quoteType": "EQUITY", "symbol": "1789.TW", "underlyingSymbol": "1789.TW", "shortName": "SCINOPHARM TAIWAN LTD", "longName": "ScinoPharm Taiwan, Ltd.", "firstTradeDateEpochUtc": 1317258000, "timeZoneFullName": "Asia/Taipei", "timeZoneShortName": "CST", "uuid": "bd1a8e04-2ee8-37cb-b2ad-8ad20dcc3939", "messageBoardId": "finmb_23777499", "gmtOffSetMilliseconds": 28800000, "currentPrice": 26.2, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 4294708992, "totalCashPerShare": 5.431, "ebitda": 829102976, "totalDebt": 676673024, "quickRatio": 6.161, "currentRatio": 7.87, "totalRevenue": 3264045056, "debtToEquity": 6.475, "revenuePerShare": 4.128, "returnOnAssets": 0.021470001, "returnOnEquity": 0.0337, "grossProfits": 1250772000, "freeCashflow": 465340000, "operatingCashflow": 773790976, "earningsGrowth": 0.891, "revenueGrowth": 0.412, "grossMargins": 0.3832, "ebitdaMargins": 0.25401, "operatingMargins": 0.124230005, "financialCurrency": "TWD", "trailingPegRatio": null}